ARCT

#3505
Arcturus Therapeutics Holdings Inc. Common Stock
8.68 USD
+2.60%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
8.68
8.68
Jahresspanne
5.86
24.14
Tagesänderung
+2.60%
Monatliche Änderung
+27.84%
6 month change
-59.23%
Jahresänderung
-15.73%
Vorheriger Schlusskurs
8.46
Eröffnung
8.68
Bid
Ask
Tief
8.68
High
8.68
Volumen
61
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 246.71 M
  • Employee 111
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-2.55
Preis-Umsatz-Verhältnis
2.05

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

Nachrichten